

JUL 20 2005

510(k) SUMMARY
as required per 807.92(c)

K051628

Submitter's Name and Address: Draeger Medical Systems, Inc.
16 Electronics Avenue
Danvers, MA 01923

Contact Person: Penelope H. Greco
Regulatory Affairs Manager
Tel: (978) 907-7503
Fax: (978) 750-6879

Date submission was prepared: June 17, 2005

Device Name:

Common Name: Monitor, Physiological, Patient
(with arrhythmia detection or alarms)
Classification Name: MHX
Regulation Number: 21 CFR 870.1025
Class: 2

Legally Marketed Device Identification: Infinity Modular Monitors

Device Description:

The intent of this 510(k) is to submit a modification specific to Scio, a gas module used exclusively with Draeger Medical Systems' Infinity monitors. The modification is the addition of a sample gas return kit identical to that of Draeger Medical's Vamos, 510(k) K040847. The modification allows the user the option of returning the sample gas from the Scio gas module to the breathing circuit.

Intended Use:

The Infinity Modular Monitors are intended for multi-parameter patient monitoring. The devices will produce visual and audible alarms if any of the physiological parameters monitored vary beyond preset limits and timed or alarm recordings will be produced. These devices will connect to an R50 Bedside recorder, either directly or via the Infinity Network.

Predicate Devices:

Infinity Monitors with Scio: 510(k) K031340, K033957, K040188
Vamos: K040847

Substantial Equivalence:

Scio with sample gas return was tested in accordance with internal design control procedures and was determined to be as safe and effective for its intended use as the predicate device.

COMPANY CONFIDENTIAL



JUL 20 2005

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Penelope H. Greco
Regulatory Affairs Manager
DRAEGER Medical Systems, Incorporated
16 Electronics Ave.
Danvers, Massachusetts 01923

Re: K051628
Trade/Device Name: Infinity Monitors with SCIO Modifications
Regulation Number: 21 CFR 870.1025
Regulation Name: Arrhythmia detector and alarm (including ST-segment
measurement and alarm)
Regulatory Class: II
Product Code: MHX
Dated: June 17, 2005
Received: June 20, 2005

Dear Ms. Greco:


We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu Lin, PH.D.
Director
Division of Anesthesiology, General Hospital
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): _____

Device Name: Infinity Modular Monitors with Scio Modifications

Indications for Use:

The INFINITY Modular monitors are capable of monitoring:

- Heart rate
- Respiration rate
- Invasive pressure
- Non-invasive pressure
- Arrhythmia
- Temperature
- Cardiac output
- Arterial oxygen saturation
- Pulse rate
- Apnea
- ST Segment Analysis
- 12-Lead ST Segment Analysis
- tcpO2/tcpCO2
- EEG signals
- FiO2

Prescription Use
 (Per 21 CFR 801.109)

OR

Over-The-Counter Use

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Sulita Y. Michael Omid

(Division Sign-Off)
Division of Anesthesiology, General Hospital,
Infection Control, Dental Devices

510(k) Number: K051628

Indications for Use

The SCIO module samples breathing gases from adults and pediatrics. The gas modules continuously measure the content of CO₂, N₂O, O₂ and one of the anesthetic agents, halothane, isoflurane, Enflurane, Sevoflurane and Desflurane in any mixture and communicates real time and derived gas information to the INFINITY monitors.

With etCO₂ the monitors can measure end tidal carbon dioxide, inspired carbon dioxide, and respiration rate in either mainstream or side-stream measurement mode; and with etCO₂+Respiratory Mechanics, spirometry and carbon dioxide can be monitored. The monitors can interface with specific third party devices via an MIB protocol converter.

The devices are intended to be used in the environment where patient care is provided by Health-care Professionals, i.e. Physicians, Nurses, and Technicians, who will determine when use of the device is indicated, based upon their professional assessment of the patient's medical condition.

The devices are intended to be used on Adult, Pediatric and Neonatal populations, *with the exception of the parameter Cardiac Output, ST Segment Analysis, and arrhythmia which are intended for use in the adult and pediatric populations only; and tcpO₂ which is to be used in the neonatal population only when the patient is not under gas anesthesia.*

MRI Compatibility Statement:

The INFINITY Modular Monitors are not compatible for use in a MRI magnetic field.



(Division Sign-Off)
Division of Anesthesiology, General Hospital,
Infection Control, Dental Devices

510(k) Number: K051628